Treatments for IC-MPGN include immunosuppressants, steroids ... Upcoming anti-complements such as iptacopan and pegcetacoplan present realistic therapeutic options for complement-related diseases.

Apellis (APLS) stock jumped 8% Monday after the company announced preliminary Q4 and 2024 revenue results along with several ...

Maximizing EMPAVELI’s impact in rare diseases through leadership in nephrology Submission of a supplemental new drug application (sNDA) expected in early 2025 for C3G and primary IC-MPGN, two rare ...

Proteinuria reduction was consistent across broad patient subgroups including adolescent and adult patients, C3G and IC-MPGN ...